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The ketogenic diet (KD) is an established, effective, nonpharmacologic treatment for children with 
pharmacoresistant epilepsy. Although the KD is the most well-established dietary therapy for epilepsy, 
it is too restrictive and is associated with serious complications; therefore, alternative lower-fat diets, 
including a modified Atkins diet and low-glycemic index diet, have been developed. Recent ongoing 
clinical evidence suggests that other dietary therapies have an efficacy almost comparable to that of 
the KD. In addition, a diet rich in polyunsaturated fatty acids appears to increase the efficacy of diet 
therapy and reduce the complications of a high-fat diet.  Here, we review the systematic information 
about lower-fat diets and better-quality dietary therapies and the current clinical status of each of these 
dietary approaches.
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Introduction
Fasting as a treatment for epilepsy was described in the New Testament of the Bible, 
and the earliest scientific approach was introduced by Geyelin in the 1920s1). Since its 
resurgence in the mid-1990s, the ketogenic diet (KD) has been used worldwide, including 
Korea, and is recognized as a valuable adjunct therapeutic modality2). The classic KD, with 
a nonfat-to-fat ratio of 1:4, necessitates a regimen that is high in fat, adequate in protein 
(1 g/kg/day), and low in carbohydrates. Since 1 g of fat produces 9 cal and 1 g of protein 
or carbohydrate produces 4 cal, when the ratio of constituents are calculated on a calorie 
scale, the ratio appears more exaggerated3) (Fig. 1). The KD is difficult to maintain due to 
its restrictive nature, and it has potentially serious complications. We require alternative 
diet therapies, including a modified Atkins diet (MAD), low-glycemic index diet (LGID), 
and a diet rich in polyunsaturated fatty acids (PUFAs), that are safer and more convenient 
to use and can improve the outcome.
Here, we discuss the systematic information and current clinical status of each of these 
dietary approaches.
What is the KD?
The composition of the KD is expressed by a 4:1 ratio of fat to protein and carbohydrate 
(by weight). The traditional long-chain fatty acid diet is the most common KD used4). The 
medium-chain triglyceride diet increases the palatability of the KD and is substantially 
more ketogenic than the classic KD, but is used less frequently because it often causes 
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gastrointestinal (GI) problems5,6). However, the efficacy of seizure 
control in these diets is similar6). There is a large clinical database 
of evidence on the efficacy of the KD, and most studies show 
similar outcomes7-10). Our experience using the classic KD for 
199 children with pharmacoresistant epilepsy suggests that after 
12 months on the KD, approximately 41% of the children had 
at least a 50% reduction in the number of seizures and 25% of 
children were seizure-free8). Although the efficacy of the KD is 
not maintained in all patients after they discontinue the diet, the 
effects of the KD persist in most patients as seen by an alleviation 
of symptoms that appeared in the pre-KD administration period 
11). The widespread acceptance of the KD has ended the debate 
about its efficacy. However, despite this, many families and 
physicians are reluctant to use the KD because of its inherent dif-
ficulties as well as the various complications that can stem from 
the nutritionally unbalanced composition of the KD. 
As a safer and more comfortable diet therapy, MAD or LGID 
could be considered. Fat is ketogenic and carbohydrate is antike-
togenic. Therefore, these diets induce a state of ketosis by pro-
viding high fat and low carbohydrate, although they involve 
intake of large amounts of protein, which is restricted in the 
conventional KD8-10). Therefore, a more tolerable diet with a re-
duced risk of the complications is desired.
Complications of KD
Poor tolerability and the potentially serious complications of 
an unbalanced diet should be considered. Some adverse events 
occur within a few days or a month of diet initiation; other events 
may occur after several months. According to our experience 
using KD therapy at Severance Hospital12), the most common early 
onset complication is GI disturbances such as nausea/vomiting, 
diarrhea, and constipation. These complications are sometimes 
associated with gastritis and fat intolerance. Other early onset 
complications, in order of frequency, are hypertriglyceridemia; 
transient hyperuri cemia, hypercholesterolemia, various infectious 
diseases, symptomatic hypoglycemia, hypoproteinemia, hypo-
magnesemia, repetitive hyponatremia, low concentrations of 
high-density lipoprotein, lipoid pneumonia due to aspiration, 
hepatitis, acute pancreatitis, and persistent metabolic acidosis. 
Late-onset complications also include osteopenia, renal stones, 
cardiomyopathy, secondary hypocarnitinemia, and iron-defi-
ciency anemia. Most early and late-onset complications are 
transient and can be successfully managed by careful follow-up 
and conservative strategies. However, 22 of 129 patients (17.1%) 
stopped the KD due to various kinds of serious complications and 
4 of 129 patients (3.1%) died during the KD: 2 from sepsis, 1 from 
cardiomyopathy, and 1 from lipoid pneumonia12). The KD is re-
strictive and has various complications; therefore, the use of other 
possible alternative lower-fat and better-quality diets, including 
the MAD, LGID, and a PUFA-rich diet, is encouraged.
MAD 
The Atkins diet was created in the 1970s by the late Dr. Robert 
C. Atkins, as a means to combat obesity. It is nearly a balanced 
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Fig. 1. The ratio of diet composition of the classic ketogenic diet (A0, a modified Atkins diet (B), and low-
glycemic index diet (C), compared to that of a regular diet (D) on a calorie scale. 
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diet (60% fat, 30% protein, and 10% carbohydrate by weight, or 
77% fat, 17% protein, and 6% carbohydrate by calorie) compared 
with the KD (80% fat, 15% protein, and 5% carbohydrate by 
weight, or 90% fat, 6% protein, 4% carbohydrate by calorie) (Fig. 
1). The protocol of an MAD suggests that carbohydrates should 
be restricted to 10 g per day in the first month13). If a child has 
difficulty with this initial restricted amount, then an increase of 5 
g per day is allowed for at least 1 month, to a maximum of 10% 
carbohydrates per day (by weight). Multivitamins, calcium, and 
vitamin D2 were administered as supplements. We recommended 
that patients consume 75% of their recommended daily calorie 
intake, which is different from the Hopkins protocol and similar 
to the conventional KD14). This recommendation was based on 
our previous experience, albeit anecdotal, of more favorable 
outcomes using the MAD with restricted calories14). In addition, 
we recommended that patients frequently measure urine ketone 
levels at home, especially when seizures occur or the frequency 
of the seizures increases. The patients’ tolerability of the diet and 
complications were assessed using various methods, including 
laboratory evaluations, on a regular basis (Table 1).
The most previous series showed striking similarities to large 
prospective and retrospective studies of the classic KD; however, 
we found a trend for a higher incidence of responders (>50% 
seizure reduction) in the KD group15), and the KD and MAD need to 
be compared in a well-controlled, randomized study in order to 
ensure a good evidence base for decisions in the usual situations. 
In contrast with the efficacy, there was no doubt about the 
tolerability of the MAD15-19). Therefore, a MAD diet is strongly 
recommended for patients who experience problems with the 
conventional KD, which was shown to be effective but too re-
strictive, as well as for patients who require a long-term diet 
therapy trial due to the presence of glucose transporter type 1- 
deficiency syndrome or selected mitochondrial diseases.
LGID
The glycemic index provides a measure of how quickly levels 
of glucose in the blood increase after consuming a particular type 
of food, relative to the consumption of pure glucose. Glycemic 
indices of various food are presented in Table 2. The LGID 
would reduce blood glucose by altering the quality and types 
of carbohydrates consumed. The LGID for refractory epilepsy 
was first reported by Pfeifer and Thiele20) in 2005. Glucose has 
a glycemic index of 100. In the LGID, foods are limited to those 
with a glycemic index of less than 50. Total carbohydrates are 
gradually decreased to 40–60 gm/day (~10% of daily calories). 
Approximately 20–30% of calories are from protein and 60–70% 
are from fat (Fig. 1). Muzykewicz et al.21) reported that a >50% 
reduction in seizure frequency in 76 patients was observed in 
42%, 50%, 54%, and 66% of patients with follow-up available at 
1, 3, 6, 9, and 12 months. The LGID seems to have efficacy similar 
to that seen in the KD observational studies, but there are no 
randomized controlled trials studies comparing the KD with the 
LGID. Thus, further studies are needed to evaluate and compare 
the efficacies of these diets.
Table 1. The suggested protocol of a modified Atkins diet at Severance Hospital
Carbohydrates were restricted to 10 g per day for the first month.
Permitted to increase by only 5 g per day up to 10% carbohydrate by weight with an interval of at least one month.
L-carnitine, multivitamins, and calcium, and vitamin D2 were given as supplements.
Calories are recommended to be restricted into 75% of recommended daily intake.
Seizure diary, blood or urine ketones semiweekly, and weight mont hly, height every 6 months
Medication changed to tablet or sprinkle (non liquid) preparations
All the patients had been advised to remain at the hospital for 3 or 4 days to ensure adequate diet adaptation to have their blood ketosis carefully monitored.
Low-carbohydrate, store-bought products (e.g., shakes, candy bars, and baking mixes) discouraged.
We recommended a trial of the diet for at least 2 months, even in the face of unfavorable results. 
Table 2. Glycemic indices of various foods
Classification GI range Example
Low GI 55 or less Most fruits and vegetables (except potatoes and watermelon), grainy breads, pasta, legumes/pulses, milk, yoghurt, products extremely 
low in carbohydrates (some cheeses, nuts), fructose
Medium GI 56–69 Whole wheat products, basmati rice, sweet potato, table sugar
High GI 70 and above Corn flakes, rice krispies, baked potatoes, water melon, croissants, white bread, extruded breakfast cereals, most white rices, straight 
glucose
GI, glycemic index.
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PUFA-enriched diet 
Fatty acids are the most important contributor to calories in 
the KD and are important for all aspects of efficacy and com-
plications of the KD12). Unfortunately, however, most fatty acids 
in the conventional KD are saturated or monounsaturated 
because the diet is based primarily on butter, cream, and olive 
oil22). PUFAs are believed to favorably affect neuronal and car-
dio vascular function23). 
There are 2 groups of PUFAs: n-3 and n-6 PUFAs. Among 
dietary n-3 PUFAs, alpha-linoleic acid (ALA) is found in flax 
seeds, walnuts, and almonds, and eicosapentaenoic acid and 
docosahexanoic acid are found in marine fish and seals. The 
primary n-3 PUFA in the brain is DHA, and it can be obtained 
directly from the diet or can be synthesized from ALA23). In addi-
tion, the conversion of ALA to DHA can be optimized when ALA 
is coadministered with the n-6 fatty acid LA at a 1:4 ratio, as 
observed in rat brains24). The n-6 PUFAs are found in vegetable 
oils such as canola and corn oil. Canola oil also has large amounts 
of n-3 and a 1:4 ratio of n-3 to n-6. 
Recent evidence suggests that the KD may be useful in the 
treatment of epilepsy owing to the presence of PUFAs25). PUFAs 
stimulate mitochondrial biogenesis and enhance energy reserves, 
leading to stabilized synaptic function and improved seizure 
control. Clinically, Fraser et al.26) described 9 children on the KD 
whose elevated blood PUFAs were correlated with improved 
seizure control. Recently, we reported the case of a 7-year-old boy 
with Lennox-Gastaut syndrome combined with mitochondrial res-
piratory chain complex I deficiency, whose medically intractable 
seizures were successfully controlled with a PUFA-enriched 
MAD without any significant adverse events. The diet consists of 
canola oil and diverse menu items such as fish and nuts (instead 
of olive oil) and has an ideal 1:2.8 ratio of n-3 to n-6 (Table 3). In 
addition, some studies suggest that n-3 and n-6 PUFAs together may 
be clinically important for preventing cardiovascular dis orders27). 
The ratio of n-3 to n-6 PUFAs is known to be important for 
maintaining cardiovascular health27). In our patient, a modified 
diet therapy with canola oil and a diverse menu resulted in an 
ideal ratio of n-3 to n-6 PUFAs of 1:2.8, and the diet is expected 
to decrease the risk for cardiovascular complications, even with 
long-term maintenance of the high-fat diet.
Conclusions
The ability of children with pharmacoresistant epilepsy to 
tolerate the MAD or LGID is encouraging, suggesting that this 
diet can replace the conventional KD, especially in patients who 
require long-term diet therapy trial due to the presence of glucose 
transporter type 1-deficiency syndrome or selected mitochondrial 
diseases, as well as in patients who experience problems with the 
conventional KD, which is effective but too restrictive. PUFA-
enriched diet therapy is also expected to increase the efficacy of diet 
therapy and reduce complications of a high-fat diet in children 
with refractory epilepsy. However, there are few evidence-based 
studies that compare the conventional KD with the MAD, LGID, 
or PUFA-enriched diet, and such further studies are needed.
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